← Back to Search

Non-invasive Brain Stimulation

Brain Stimulation for ADHD

N/A
Recruiting
Research Sponsored by Bradley Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up theta-gamma coupling will be obtained before the 1st session, and 24 hours after the 1st, 5th, and 10th sessions. statistical modeling will examine the change across these four time points. this change is considered a single primary outcome variable.
Awards & highlights

Summary

This trial tests if a device that sends small electrical pulses to the brain can help teenagers with ADHD improve their memory and attention. The treatment targets a specific brain area to make brain waves work better together.

Who is the study for?
This trial is for teenagers aged 13-18 with ADHD, an IQ over 80, and specific working memory challenges. They must have a clinical diagnosis of ADHD confirmed by the NICHQ Vanderbilt Assessment Scales-Parent and be fluent in English. Participants can continue their current ADHD treatments but cannot change them during the study.
What is being tested?
The trial tests Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex on teens with ADHD. It aims to see if this non-invasive brain stimulation can improve symptoms by affecting brain activity related to attention and impulsivity.
What are the potential side effects?
While not explicitly listed, potential side effects may include discomfort at the stimulation site, headache, lightheadedness or seizures; however these are generally rare with non-invasive brain stimulation techniques.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~adhd/working memory symptoms will be obtained before the 1st session, and 24 hours after the 1st, 5th, and 10th sessions. statistical modeling will examine the change across these time points. this change is considered a single primary outcome variable.
This trial's timeline: 3 weeks for screening, Varies for treatment, and adhd/working memory symptoms will be obtained before the 1st session, and 24 hours after the 1st, 5th, and 10th sessions. statistical modeling will examine the change across these time points. this change is considered a single primary outcome variable. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Parent-Reported ADHD & Working Memory-Related Symptoms
Change in Theta-Gamma Coupling
Change in Working Memory Test Performance

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active intermittent Theta Burst StimulationActive Control1 Intervention
Participants will complete 10 daily sessions of active iTBS to the left dorsolateral prefrontal cortex
Group II: Sham intermittent Theta Burst StimulationPlacebo Group1 Intervention
Participants will complete 10 daily sessions of sham iTBS to the left dorsolateral prefrontal cortex

Find a Location

Who is running the clinical trial?

Bradley HospitalLead Sponsor
17 Previous Clinical Trials
1,536 Total Patients Enrolled
3 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
295 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Media Library

Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex (Non-invasive Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05102864 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Sham intermittent Theta Burst Stimulation, Active intermittent Theta Burst Stimulation
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex Highlights & Side Effects. Trial Name: NCT05102864 — N/A
Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex (Non-invasive Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05102864 — N/A
~6 spots leftby Oct 2025